Morgan Stanley Upgrades Charles River Laboratories to Overweight, Raises PT to $220

Morgan Stanley upgraded shares of Charles River Laboratories International (NYSE: CRL) to Overweight from Equalweight and raised its price target to $220 from $185, according to a report from Insider Monkey.

Rating Change

• Previous Rating: Equalweight
• New Rating: Overweight
• Previous Price Target: $185
• New Price Target: $220

Analyst Rationale

Morgan Stanley expressed optimism about Charles River Laboratories' long-term growth prospects, leading to the upgrade and price target increase. The report did not provide further details on the specific drivers, but the move likely reflects confidence in the company's position in the research services and pharmaceutical contract space.

Context

Charles River Laboratories is a top stock pick at Ariel Investments, which included it in its list of best stocks to buy. The upgrade comes amid volatility in the biotech sector, but analysts remain positive on companies providing essential services to the pharmaceutical industry.

What to Make of It

Morgan Stanley's upgrade reflects a positive long-term view on Charles River Laboratories. However, investors should consider sector risks and current valuation before making investment decisions.